|
||||||||||
|
National
Hepatitis C Prevention Strategy TABLE OF CONTENTS
Executive Summary The National Hepatitis C Prevention Strategy is CDC’s response to this request, and includes partnerships and coordination with the Agency for Healthcare Research and Quality (AHRQ), Food and Drug Administration (FDA), Health Care Financing Administration (HCFA), Health Resources and Services Administration (HRSA), National Institutes of Health (NIH), Substance Abuse and Mental Health Services Administration (SAMHSA), and other federal, state, and private sector agencies. This CDC strategy serves to protect the public’s health by preventing and controlling HCV infection; enhancing health decisions by providing credible information on hepatitis C; and promoting healthy living through strong partnerships with national, State, and local organizations in both the public and private sectors. The goals of the National Hepatitis C Prevention Strategy are to lower the incidence of acute hepatitis C in the United States and reduce the disease burden from chronic HCV infection. Achievement of these goals requires: 1) harm reduction programs directed at persons at increased risk for infection to reduce the incidence of new HCV infections; 2) counseling, testing, and medical evaluation and management of infected persons to control HCV-related chronic liver disease; 3) surveillance to evaluate the effectiveness of prevention activities; and 4) research to provide answers to questions pertinent to the prevention and control of hepatitis C. The principle components of the National Hepatitis C Prevention Strategy are:
Hepatitis C
prevention activities must be
accessible to persons receiving health care services in both the public
and private sectors. The most effective means to prevent HCV infection and
its consequences is to integrate hepatitis C prevention activities into
existing clinical services and public health programs, such as those for
the prevention and treatment of human immunodeficiency virus
(HIV)/Acquired Immune Deficiency Syndrome (AIDS), sexually transmitted
diseases (STDs) and drug abuse. Similar risk factors place persons at risk
for transmission of the major bloodborne viral infections – HIV, HCV,
and hepatitis B virus (HBV). Effective implementation of the National
Hepatitis C Prevention Strategy should reduce the number of new HCV
infections, further reduce other bloodborne virus infections, and prevent
the projected increase in chronic liver disease due to hepatitis C.
|
(888)4-HEP-CDC
This page last reviewed October 1, 2004 All
information presented in these pages and all items available for download
are for public use. US Department of Health and Human Services Privacy Policy | Accessibility |